ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0548 • ACR Convergence 2020

    Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases. Prospective Data After Five Years of Follow Up

    Maria Auxiliadora Martin-Martinez1, Santos Castañeda2, Fernando Sanchez-Alonso3, Carmen García-Gómez4, Carlos González_Juanatey5, M. Ángeles Belmonte-López6, Jesus Tornero-Molina7, José Santos-Rey8, Carmen Olga Sánchez-González9, Estefania Moreno10, Maria del puerto Moreno-Gil11, Tatiana Cobo-Ibañez12, Jose Antonio Pinto-Tasende13, Jesús Babío-Herráez14, Gema Bonilla15, Antonio Juan-Mas16, Francisco Manero-Ruiz17, Montserrat Romera-Baurés18, Javier Bachiller-Corral19, Eugenio Chamizo-Carmona20, Javier Calvo-Catalán21, Raimon Sanmartí22, Celia Erausquin-Arruabarrena23, Rosario Garcia-Vicuña24, Carmen Barbadillo25, Sergio Ros-Expósito26, Ana Isabel Turrión27, M José González-Fernández28, Jose Miguel Senabre29, Silvia Martínez-Pardo30, Ana Ruibal-Escribano31, Emilio Giner-Serret32, Elisabet Berzosa-Sola33, Julia Martínez-Barrio34, Encarnación Pagán35, M Enriqueta- Peiró36, Sagrario Bustabad-Reyes37, Alba Erra-Durán38, Beatriz González Álvarez39, Ana Cruz Valenciano40, Javier Rivera-Redondo41, Manuel Moreno Ramos42, Sergio Rodriguez Montero43, Mercedes Morcillo-Valle44, Maria Teresa Navío45, Maria Galindo-Izquierdo46, Manuel Riera-Soler47, Jordi Fiter48, Javier Llorca49 and Miguel Ángel González-Gay50, 1Spanish Society of Rheumatology, Madrid, Spain, 2Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 3Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, 4Consorci Sanitari de Terrassa, Barcelona, Spain, 5Hospital Lucus Augusti, Lugo, Spain, 6Hospital Regional Universitario Carlos Haya, Malaga, Spain, 7University Hospital of Guadalajara. Spain, Madrid, Madrid, Spain, 8Hospital Virgen de la Salud, Toledo, Spain, 9Hospital Sureste, Madrid, Spain, 10Universitario Vall D'hebron, Barcelona, Spain, 11Complejo Hospitalario de Cáceres, Caceres, Spain, 12Hospital Infanta Sofia, Madrid, Spain, 13CHUAC, A Coruña, Spain, 14Hospital de Cabueñes, Gijón, Spain, 15Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, 16Hospital Sont Llatzer, Palma de Mallorca, Spain, 17Hospital Universitario Miguel Servet, Zaragoza, Spain, 18Hospital Universitario de Bellvitge, Barcelona, Spain, 19Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 20Hospital de Merida, Badajoz, Spain, 21Hospital General Universitario Valencia, Valencia, Spain, 22Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, 23Hospital de Gran Canaria Dr. Negrín, Gran Canaria, Spain, 24Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, 25Hospital Universitario Puerta de Hierro, Madrid, Spain, 26Hospital Viladecans, Barcelona, Spain, 27Hospital Universitario de Salamanca, Salamanca, Spain, 28Hospital Dexeus, Barcelona, Spain, 29Hospital de Marina Baixa, Alicante, Spain, 30H. Mutua de Terrassa, Barcelona, Catalonia, Spain, 31Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, 32Hospital Obispo Polanco, Teruel, Spain, 33Hospital del Elda, Alicante, Spain, 34Hospital General Universitario Gregorio Marañón, Madrid, 35Hospital Los Arcos, Murcia, Spain, 36Hospital Marques de Valdecilla, Santander, Spain, 37Hospital Universitario Canarias, Tenerife, Spain, 38Hospital San Rafael, Barcelona, Spain, 39Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain, 40Hospital Severo Ochoa, Madrid, Spain, 41Instituto Provincial de Rehabilitación, Madrid, Spain, 42Hospital Virgen de la Arrixaca, Murcia, Spain, 43H. Virgen de Valme, Sevilla, Spain, 44Hospital El Escorial, Madrid, Spain, 45Hospital Infanta Leonor, Madrid, Spain, 46Hospital Universitario 12 de Octubre, Madrid, Spain, 47Hospital dos de Maig, Barcelona, Spain, 48Hospital Universitario Son Dureta, Palma de Mallorca, Spain, 49School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, 50Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular (CV) event (CVE) in patients with chronic inflammatory rheumatic diseases…
  • Abstract Number: 0562 • ACR Convergence 2020

    The Relationship Between Heart Disease Risk Profile and Osteoarthritis, Overall and by Multi-/Single-Joint Involvement

    Anthony Perruccio1, Shatabdy Zahid2, Calvin Yip3, J Denise Power2, Mayilee Canizares2, George Heckman4 and Elizabeth Badley1, 1Krembil Research Institute, UHN; University of Toronto, Toronto, ON, Canada, 2Krembil Research Institute, University Health Network, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4University of Waterloo, Waterloo, ON, Canada

    Background/Purpose: Osteoarthritis (OA) and heart disease (HD) are among the most common chronic conditions. Several studies have shown that OA increases the risk of HD…
  • Abstract Number: 0561 • ACR Convergence 2020

    Risk Factors for Falls Among Individuals with Knee OA: A Longitudinal Community-based Study

    Jessica Wilfong1, Anthony Perruccio2 and Elizabeth Badley2, 1Krembil Research Institute, University Helath Network, Toronto, ON, Canada, 2Krembil Research Institute, UHN; University of Toronto, Toronto, ON, Canada

    Background/Purpose: Knee osteoarthritis (OA) is a known risk factor for falling, but little is known about what factors contribute to the risk of falling among…
  • Abstract Number: 0567 • ACR Convergence 2020

    Rheumatologist’s Perception of the Efficacy, Safety and Willingness to Prescribe Infliximab and Use Alternate Drug Supply Programs to Lower Cost of Rheumatoid Arthritis Care

    Cesar Galan1, Alan Puric2, Guy Cozzi2, Michele Hamburger3, Elisea Avalos-Reyes4 and Kjel Johnson1, 1CVS Health, Lincoln, RI, 2CVS Health, Northbrook, IL, 3Frances Hamburger Institute, Hauppauge, NY, 4CVS Health, Irving, TX

    Background/Purpose: There is interest in employing biosimilar therapies for patients with rheumatoid arthritis (RA), which have been shown comparable to originator biologics in safety and…
  • Abstract Number: 0566 • ACR Convergence 2020

    Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries

    Shirley Huang1, Xintong Li2, Joehl Nguyen2, Jacob Robinson2, Susan Hogan3, Vimal Derebail3 and Carolyn Thorpe2, 1University of North Carolina at Chapel Hill, Chapel Hill, 2University of North Carolina Eshelman School of Pharmacy, Chapel Hill, 3University of North Carolina Kidney Center, Chapel Hill

    Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) vasculitis (AV) is a complex group of autoimmune disorders affecting blood vessels in multiple organ systems. Delays in diagnosis are…
  • Abstract Number: 0572 • ACR Convergence 2020

    Two-year Cost-effectiveness Between Two Gradual Tapering Strategies in Rheumatoid Arthritis: Cost-utility Analysis of the TARA Trial

    Elise van Mulligen1, Angelique Weel2, Mieke Hazes3, Annette van der Helm - van Mil4 and Pascal de Jong1, 1Erasmus MC, Rotterdam, Netherlands, 2Erasmus School of Health Policy & Management, Maasstad hospital, Erasmus MC, Rotterdam, Netherlands, 3Erasmus Medical Center, Rotterdam, Netherlands, 4Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: The benefits of tapering are a decreased risk of long-term adverse events and a reduction of health care costs, especially when bDMARDs are tapered.…
  • Abstract Number: 0574 • ACR Convergence 2020

    Is Hydroxychloroquine Use a Proxy for Health Care Access? Predictors of First Dispensing Among Medicaid Beneficiaries with Incident Lupus

    Katherine Pryor1, Chang Xu1, Jamie Collins1, Karen Costenbader2 and Candace Feldman1, 1Brigham and Women's Hospital, Boston, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Hydroxychloroquine/chloroquine (HCQ/CQ) is considered to be the backbone of systemic lupus erythematosus (SLE) care. Differences in receipt of HCQ/CQ may exacerbate disparities in adverse…
  • Abstract Number: 0569 • ACR Convergence 2020

    Ability and Willingness to Utilize Telemedicine Among Rheumatology Patients – a Cross Sectional Survey

    Steve Kong1, Lilian Otalora Rojas2, Amnie Ashour3, Mathew Robinson1 and Neha Bhanusali1, 1University of Central Florida College of Medicine, Orlando, 2University of Central Florida HCA Healthcare GME, Orlando, 3Stony Brook University School of Medicine, New York

    Background/Purpose: Telemedicine (TM) is the delivery of health care services using information and communication technologies. TM presents unique opportunities and benefits specifically in rheumatology as…
  • Abstract Number: 0564 • ACR Convergence 2020

    Incidence and Progression of Foot Osteoarthritis

    Rami Eltaraboulsi1, Amanda Nelson2, Carolina Alvarez3, Jordan Renner4, Catherine Bowen5, Lucy Gates5 and Yvonne Golightly6, 1University of North Carolina at Chapel Hill, Apex, NC, 2University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, 3University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Miami, FL, 4University of North Carolina, Chapel Hill, NC, 5University of Southampton, Southampton, United Kingdom, 6University of North Carolina at Chapel Hill Dept of Epidemiology, Chapel Hill, NC

    Background/Purpose: Foot osteoarthritis (OA) is a common cause of disability in older adults yet remains an understudied area. The purpose of this study was to…
  • Abstract Number: 0577 • ACR Convergence 2020

    Qualitative Review of Unsuccessful Pilot Study of Super-Utilizer Systemic Lupus Erythematosus (SLE) Patients Enrollment into Team Based Program to Improve Patient Outcomes

    Sarah Min1, Devy Setyono2, Sunghye Kim3, Feben Girma1, Melanie Martin1 and Rachel Wolfe1, 1Wake Forest Baptist Medical Center, Winston-Salem, NC, 2Emkey Arthritis and Osteoporosis Clinic, Wyomissing, PA, 3W.G. Hefner VA Medical Center, Salisbury, NC

    Background/Purpose: SLE is a chronic multi-system autoimmune disease, affecting mostly women of child-bearing age and more racial minorities, with a wide spectrum of outcomes: from…
  • Abstract Number: 0580 • ACR Convergence 2020

    Risk of Severe Acute Localized Reactions for Different Intra-Articular Hyaluronic Acid Knee Injections in a Real World Setting

    Kevin Ong1, Jack Farr2, Louis McIntyre3, Andrew Gudeman2, Iain Murray4, Charles Hummer5, Wilson Ngai6, Heather Good7, Edmund Lau8 and Roy Altman9, 1Exponent, Philadelphia, 2Indiana University Department of Orthopaedic Surgery, Indianapolis, 3US Orthopedics, Tarrytown, 4Department of Orthopaedics, The University of Edinburgh, Edinburgh, United Kingdom, 5Premier Orthopaedics and Sports Medicine, Glen Mills, 6Sanofi US, Bridgewater, 7Sanofi US, Bridgewater, FL, 8Exponent, Menlo Park, 9David Geffen School of Medicine, University of California, Agua Dulce, CA

    Background/Purpose: Case reports of severe acute localized reactions (SALR) following intra-articular (IA) hyaluronic acid (HA) injections for knee osteoarthritis (OA) have been described. These have…
  • Abstract Number: 0581 • ACR Convergence 2020

    A Proposed Economic Framework to Model the Consequences of Psoriatic Arthritis Disease Domains

    Jacquelyn Chou1, Ervant Maksabedian2, David Collier3 and Howard Thom4, 1PRECISION heor, Los Angeles, CA, 2Amgen Inc., LOS ANGELES, CA, 3Amgen, Thousand Oaks, CA, 4University of Bristol, Bristol, England, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) manifests heterogeneous signs and symptoms (e.g., dactylitis, enthesitis, axial involvement, skin- and nail disease), which may respond to treatments differently. While…
  • Abstract Number: 0576 • ACR Convergence 2020

    Medical Savings of Timely Rheumatoid Arthritis Diagnoses

    Kathryn Johnson1, Christine Sawicki1, Cristina Sotelo2, Tanvi Kalevar3, Sylvie Lardeux4, Fabio Casadio3, David Baghdadi5, Michele Hamburger6, Elisea Avalos-Reyes7 and Kjel Johnson1, 1CVS Health, Lincoln, RI, 2CVS Health, Austin, TX, 3CVS Health, New York, NY, 4CVS Health, Wellesley, MA, 5CVS Health, Woonsocket, RI, 6Frances Hamburger Institute, Hauppauge, NY, 7CVS Health, Irving, TX

    Background/Purpose: Previous studies suggest that early rheumatoid arthritis (RA) recognition and treatment provides greater clinical benefits than treatment started later in the disease course. However,…
  • Abstract Number: 0584 • ACR Convergence 2020

    Total Cost of Care for Patients with Rheumatoid Arthritis

    Kjel Johnson1, Rebecca Karos2, Elisea Avalos-Reyes3, Fabio Casadio4, Michele Hamburger5 and Chiara Leprai4, 1CVS Health, Lincoln, RI, 2CVS Health, Wellesley, MA, 3CVS Health, Irving, TX, 4CVS Health, New York, NY, 5Frances Hamburger Institute, Hauppauge, NY

    Background/Purpose: The range of medical costs associated with rheumatoid arthritis (RA) is, in part, related to the various treatment options. Treatment for RA focuses on…
  • Abstract Number: 0579 • ACR Convergence 2020

    Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients

    Guy Cozzi1, Pavlo Kyrychenko2, Michele Hamburger3 and Elisea Avalos-Reyes4, 1CVS Health, Northbrook, IL, 2CVS Health, Norhtbrook, IL, 3Frances Hamburger Institute, Hauppauge, NY, 4CVS Health, Irving, TX

    Background/Purpose: Biologic disease-modifying antirheumatic drug (bDMARD) therapies are commonly prescribed for rheumatoid arthritis (RA) treatment. However, their high out-of-pocket (OOP) cost may limit patient access…
  • « Previous Page
  • 1
  • …
  • 663
  • 664
  • 665
  • 666
  • 667
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology